People: Celgene Corp (CELG.O)

CELG.O on Nasdaq

99.18USD
8 Feb 2016
Change (% chg)

-- (--)
Prev Close
$99.18
Open
--
Day's High
--
Day's Low
--
Volume
2,247
Avg. Vol
5,850,493
52-wk High
$140.72
52-wk Low
$92.98

Search Stocks

Alles, Mark 

Mr. Mark J. Alles has been promoted as Chief Executive Officer of the Celgene Corporation., effective March 1, 2016. He is no longer President, Chief Operating Officer of Celgene Corp. Mr. Alles joined in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles started his 27-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles currently serves as a Director for Gilda’s Club NYC, a not-for-profit organization helping people with cancer, and as a trustee of The Healthcare Institute of New Jersey.

Basic Compensation

Total Annual Compensation, USD 5,046,080
Restricted Stock Awards, USD 901,257
Long-Term Incentive Plans, USD --
All Other, USD 2,098,890
Fiscal Year Total, USD 8,046,230

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 111,406 10,048,600.00
Name Fiscal Year Total

Robert Hugin

24,236,100

Mark Alles

8,046,230

Peter Kellogg

10,097,400

Thomas Daniel

7,670,580

Jacqualyn Fouse

8,671,490

Scott Smith

3,267,870
As Of  30 Dec 2014
Search Stocks